S162
Brachytherapy - Urology
ESTRO 2026
median D90 of 155 Gy in the LR, 155Gy in IR and 122 Gy in HR, demonstrating high quality implants.Twenty- year overall survival was 86%, 80%, and 72%, prostate cancer-specific survival was 98%, 98%, and 95% and biochemical relapse-free survival was 87%, 79%, and 88%, for LR, IR and HR respectively.Our median post treatment PSA was 0.4 ng/mL and time from treatment to failure was 5.5 years.Ten-year toxicity data demonstrated an increase in genitourinary symptoms with a mean IPSS score increase of +2.5 (out of 35) which was not deemed clinically significant. Over 60% of men remained potent (IIEF-5S >11) at 10 years, and a mean bowel function score increase of +1 (out of 16), demonstrating a minimal change in symptoms.
Conclusion: Our results demonstrate excellent therapeutic outcomes, with impressive durability, in the ≤ 60 population. Given this robust evidence, we advocate for LDR brachytherapy to remain a preferred treatment modality for this patient population. Keywords: Prostate, LDR, ≤ 60 References: 1. UK CR. Prostate cancer incidence statistics 2025 [Available from: https://www.cancerresearchuk.org/health- professional/cancer-statistics/statistics-by-cancer- type/prostate-cancer/incidence#heading-Two.2. Langley SEM, Soares R, Uribe J, Uribe-Lewis S, Money- Kyrle J, Perna C, et al. Long-term oncological outcomes and toxicity in 597 men aged ≤ 60 years at time of low- dose-rate brachytherapy for localised prostate cancer. BJU Int. 2018;121(1):38-45.3. (NICE) NIfHaCE. Prostate cancer: diagnosis and management 2014 [Available from: https://www.nice.org.uk/guidance/cg175.4. Langley SE, Laing RW. 4D Brachytherapy, a novel real- time prostate brachytherapy technique using stranded and loose seeds. BJU Int. 2012;109 Suppl 1:1-6.
Made with FlippingBook - Share PDF online